Editorial · Longevity · NAD+
NAD+ in the UK: the landscape explained
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Published Mon Jun 01 2026 01:00:00 GMT+0100 (British Summer Time) · 6 min read
NAD+ (nicotinamide adenine dinucleotide) is a co-enzyme central to cellular energy metabolism, and tissue levels decline with age. In the UK it reaches consumers four ways: intravenous NAD+ at private clinics, subcutaneous or intramuscular injection courses, oral supplements, and the precursor compounds NMN and NR sold as food supplements. Ingestible forms are regulated under UK food-supplement rules; IV and injection forms sit outside medicines licensing as private clinical services. The human evidence is early and route-dependent, with no large long-term randomised trials confirming the anti-ageing claims used in marketing.
NAD+ has moved from biochemistry textbooks to clinic price lists in the space of a few years. This post sets out what the molecule is, why the longevity industry built a market around it, and how the UK routes differ. It is editorial commentary. We do not sell NAD+, and we do not recommend a route for any individual.
What NAD+ actually is
NAD+ (nicotinamide adenine dinucleotide) is a co-enzyme present in every living cell. It sits at the centre of the reactions that convert food into usable energy, and it is also consumed by repair and signalling enzymes such as the sirtuins and PARPs. Cellular NAD+ is not a vitamin you are short of in any classical deficiency sense: it is made and recycled continuously inside cells from dietary precursors, chiefly the various forms of vitamin B3.
The observation that drives the entire category is that measured NAD+ levels decline in many mammalian tissues with age. That decline is well documented in animal models and in some human tissue samples. The open question, and it is a genuinely open one, is whether topping NAD+ back up produces meaningful health outcomes in people. That is the gap between the biology and the marketing.
Why longevity clinics market it
The commercial case is straightforward. If NAD+ falls with age, and if NAD+ is required for energy and repair, then raising it sounds like a plausible intervention against ageing. Rodent studies lend surface support: NAD+ precursors raise tissue NAD+ in mice and shift several age-associated metabolic markers. Those findings are real, but mouse metabolism is not human metabolism, and a marker moving is not the same as a person living longer or better.
Published human trials so far are smaller, shorter, and more equivocal. They tend to confirm that precursors raise blood NAD+ markers and are generally well tolerated over the studied periods, while stopping short of demonstrating the dramatic outcomes the category is sold on. Studies suggest a biological effect on NAD+ levels; they do not establish that this reverses ageing or treats any condition. There are no large long-term randomised controlled trials underpinning the headline claims.
The UK routes at a glance
There are effectively four ways to encounter NAD+ in the UK, and they are not interchangeable.
Intravenous NAD+ is delivered at private wellness and longevity clinics. Sessions run for several hours and are usually repeated as a course. See our explainer on IV NAD+ in the UK.
NAD+ injection (subcutaneous or intramuscular) is offered by some clinics as a shorter alternative to the drip. We compare the two in NAD+ injection vs IV.
Oral NAD+ supplements are sold as capsules, lozenges or powders. Intact oral NAD+ is poorly absorbed, which is why most products centre on precursors instead. See NAD+ supplements in the UK.
Precursor supplements, NMN and NR, are the most common ingestible route. We cover the NAD+ vs NMN and NR vs NMN questions separately.
How UK regulation splits the routes
Oral NAD+, NMN and NR sold without medicinal claims fall under the Food Supplements (England) Regulations 2003 and equivalent rules in the devolved nations. Labelling and permitted claims are governed accordingly. NMN’s regulatory status has been the subject of back-and-forth across the UK and EU since 2022; it remains legal to sell in the UK as a food supplement, EFSA has issued a positive safety opinion, and it is not yet formally authorised as a novel food in the EU. We keep the NMN sub-hub updated as that position evolves.
IV NAD+ and injection courses are not regulated as medicines, because they are not marketed under a Marketing Authorisation. They sit under private clinical service regulation: CQC registration in England, a GMC or GPhC registered practitioner, and a GPhC registered compounding pharmacy where relevant.
Where to read next
The NAD+ sub-hub is the parent page for all of this and the best starting point. For the broader peptide context, the mitochondrial peptide MOTS-c sits adjacent to the NAD+ literature. If you are weighing a clinic visit rather than a supplement, our UK longevity clinics editorial covers the market.
For costs across every route, see NAD+ cost in the UK, and for the safety picture, what the literature notes on NAD+ side-effects.